Patents Examined by Marianne P. Allen
  • Patent number: 11827669
    Abstract: Antibodies and compositions of matter useful for the detection, diagnosis and treatment of Hepatitis B Virus infection in mammals, and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: November 28, 2023
    Assignee: THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES
    Inventors: Paul T. Wingfield, Norman R. Watts, Alasdair C Steven
  • Patent number: 11827700
    Abstract: The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making the anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6.
    Type: Grant
    Filed: November 11, 2020
    Date of Patent: November 28, 2023
    Assignee: Vitaeris Inc.
    Inventors: Leon F. Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Anderson, Benjamin H. Dutzar, Ethan W. Ojala, Brian R. Kovacevich, John A. Latham, Jeffrey T. L. Smith
  • Patent number: 11814429
    Abstract: The invention relates to PD-1 binding agents that do not block the interaction of PD-1 with its ligands, and the use of such binding agents in the treatment, prevention and detection of disease.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: November 14, 2023
    Assignee: CRESCENDO BIOLOGICS LIMITED
    Inventors: Bryan Edwards, Carolyn Edwards, James Legg, Martyna Lewandowska, Daniela Sydoruk, Colette Johnston, Christine Rossant, Yumin Teng
  • Patent number: 11802152
    Abstract: The present invention relates to monoclonal antibodies and antigen-binding fragments thereof that bind to human ?-klotho, and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: December 1, 2021
    Date of Patent: October 31, 2023
    Assignee: Novartis AG
    Inventors: Brian Boettcher, Shari Lynn Caplan, Regis Cebe, Guochun Li, John A. Taraszka, Fangmin Xu, David Langdon Yowe
  • Patent number: 11773172
    Abstract: The present disclosure provides anti-EGFR antibody polypeptides, polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the uses thereof.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: October 3, 2023
    Assignee: WUXI BIOLOGICS IRELAND LIMITED
    Inventors: Yunying Chen, Jing Li
  • Patent number: 11759499
    Abstract: This application discloses ophthalmic formulations and methods for treating and preventing corneal haze and scarring with an hepatocyte growth factor (HGF) agent.
    Type: Grant
    Filed: April 20, 2021
    Date of Patent: September 19, 2023
    Assignee: The Schepens Eye Research Institute, Inc.
    Inventors: Sunil Chauhan, Reza Dana
  • Patent number: 11760797
    Abstract: The invention provides interleukin-33 (IL-33) antibodies and methods of making and using the same, e.g., for treatment of IL-33 mediated disorders (e.g., ocular disorders such as AMD (e.g., geographic atrophy (GA)).
    Type: Grant
    Filed: March 12, 2021
    Date of Patent: September 19, 2023
    Assignee: Genentech, Inc.
    Inventors: Gerald R. Nakamura, Dhaya Seshasayee, Menno Van Lookeren Campagne, Tiffany Wong, Jia Wu, Hongkang Xi, Jack Bevers, III, Hiu Nam Chan, Laetitia Comps-Agrar, Racquel Corpuz
  • Patent number: 11732036
    Abstract: The present invention relates to anti-VEGF-A/anti-ANG2 antibodies, e.g. in the form of a bispecific Fab fragment, and methods of using the same.
    Type: Grant
    Filed: September 3, 2021
    Date of Patent: August 22, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Roland Beckmann, Sebastian Fenn, Guido Hartmann, Sabine Imhof-Jung, Kristian Hobolt-Jensen, Joerg Moelleken, Michael Molhoj, Christian Schantz, Janina Speck, Christoph Ullmer, Barbara Weiser
  • Patent number: 11732023
    Abstract: Provided herein are polypeptides that bind to a blood-brain barrier (BBB) receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a BBB receptor-expressing cell, e.g., for transport across the BBB. Also provided herein are transferrin receptor (TfR) constructs that comprise a monomeric TfR apical domain or one or more portions of the TfR apical domain which have been circularly permuted relative to the full-length TfR sequence.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: August 22, 2023
    Assignee: Denali Therapeutics Inc.
    Inventors: Xiaocheng Chen, Mihalis Kariolis, Robert C. Wells
  • Patent number: 11713353
    Abstract: Provided are constructs comprising a single-domain antibody (sdAb) moiety that specifically recognizes PD-1. Also provided are methods of making and using these constructs.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: August 1, 2023
    Assignee: Nanjing Legend Biotech Co., Ltd.
    Inventors: Yafeng Zhang, Shu Wu, Shuai Yang, Chuan-Chu Chou
  • Patent number: 11708404
    Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).
    Type: Grant
    Filed: April 13, 2022
    Date of Patent: July 25, 2023
    Assignees: Ablynx N.V., Sanofi
    Inventors: Marie-Ange Buyse, Carlo Boutton
  • Patent number: 11692046
    Abstract: The present disclosure relates to monoclonal antibodies and antigen-binding fragments thereof that bind to human ?-klotho, and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: July 4, 2023
    Assignee: Novartis AG
    Inventors: Regis Cebe, Stephane Olland, David Langdon Yowe
  • Patent number: 11684677
    Abstract: There is provided inter alia a composition comprising a TNF-alpha binding polypeptide and an IL-6R binding polypeptide.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: June 27, 2023
    Assignee: SORRISO PHARMACEUTICALS, INC.
    Inventors: Scott Crowe, Kevin Roberts, Tim Carlton, Luana Maggiore, Marion Cubitt, Mike West, Keith Ray
  • Patent number: 11673954
    Abstract: The present application provides constructs comprising a single-domain antibody (sdAb) moiety that specifically recognizes PD-L1. Also provided are methods of making and using these constructs.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: June 13, 2023
    Assignee: Nanjing Legend Biotech Co., Ltd.
    Inventors: Yafeng Zhang, Shu Wu, Shuai Yang, Chuan-Chu Chou
  • Patent number: 11673960
    Abstract: The present disclosure relates to antibody molecules that bind specifically to C-MET and related nucleic acid molecules, vectors and host cells. Also provided are medical uses of such antibody molecules. The claimed anti C-Met antibodies of the present application have been selected by in silico engineering. Some of the antibodies have been generated and further characterized after expression in mammalian expression system.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: June 13, 2023
    Assignee: LOCKBODY THERAPEUTICS LTD
    Inventor: William James Jonathan Finlay
  • Patent number: 11661454
    Abstract: The disclosure relates to an anti-VEGF-PD1 bispecific antibody with a novel structure and a use thereof, which belongs to the technical field of molecular immunology. The CDR-H1 in the heavy chain variable region of the antibody is an amino acid sequence expressed by SEQ ID NO: 1, the CDR-H2 is an amino acid sequence expressed by SEQ ID NO: 2, the CDR-H3 is an amino acid sequence expressed by SEQ ID NO: 3, and the CDR-L in the light chain variable region of the antibody is an amino acid sequence expressed by SEQ ID NO:4.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: May 30, 2023
    Assignee: ANHUI BIOX VISION BIOLOGICAL TECHNOLOGY CO., LTD.
    Inventors: Guoxing Wang, Liansheng Cheng, Siyi Hu, Hong Yuan, Ting Wu, Li Fan
  • Patent number: 11644471
    Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: May 9, 2023
    Assignees: Ablynx N.V., Sanofi
    Inventors: Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Neotere Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
  • Patent number: 11644468
    Abstract: The present invention relates to compositions and methods for the prevention or the treatment of prostate cancer, wherein said compositions comprise an antibody binding to progastrin and said methods comprise the use of an antibody binding to progastrin.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: May 9, 2023
    Assignee: Progastrine et Cancers S.à r.L
    Inventor: Alexandre Prieur
  • Patent number: 11634496
    Abstract: A method for treating or preventing vascular endothelial cell injured diseases, especially cerebral infarctions or myocardial infarctions, by administering a c-MET agonist antibody to a subject in need thereof, and specific c-MET agonist antibodies.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: April 25, 2023
    Assignee: TONGJI UNIVERSITY SUZHOU INSTITUTE BIOMEDICAL RESEARCH CENTER
    Inventors: Jianmin Fang, Ming Jiang, Yanxin Yin, Jia Guo, Lihua Yu
  • Patent number: 11633456
    Abstract: Compositions and methods for treating hair loss are provided. One embodiment provides a microneedle composition, which when administered to the skin of a subject promotes hair growth. The microneedle compositions include an effective amount of glucocorticoid-induced leucine zipper (GILZ) protein having an amino acid sequence that has 99 or 100% identity to SEQ ID NO: 1, or fragment thereof to promote hair growth when administered to the skin of the subject and a bioerodible, biodegradable, or biosorbable polymer, wherein the composition is formulated as bioerodible, biodegradable, or bioabsorbable microneedles. In one embodiment the GILZ protein or fragment thereof is conjugated to a cell penetrating peptide. The cell penetrating peptide can be TAT GRKKRRQRRRPQ (SEQ ID NO:4) or a variant thereof.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: April 25, 2023
    Assignee: Augusta University Research Institute, Inc.
    Inventors: Mahmood Mozaffari, Babak Baban